About TIA

Established in 2008, Therapeutic Innovation Australia (TIA) is the lead agent for the National Collaborative Research Infrastructure Strategy (NCRIS) "Therapeutic Innovation Australia" project funded by the Australian Department of Education, Skills and Employment. ​TIA supports national research infrastructure across three capabilities - Biologics & Vaccines, Cell & Gene Therapies, and Small Molecule Pharmaceuticals.

The TIA consortium helps researchers and industry to translate research findings down the development pipeline towards readiness for Phase I trials and beyond - from D2 through to T2 

where we fit.jpg

Phenomics Australia

Basic research to establish fundamental biologic mechanisms

Disease biology research to identify potential therapeutic targets 

Therapeutic agent discovery eg. HTS, phage display, gene therapy development

Therapeutic agent development inc. preclinical testing

Translation to humans (eg. Phase I)

Translation to patients (eg. Phase II,III)

Translation to practice

Translation to populations 

Basic research to establish fundamental biological mechanisms
Disease biology research to identify potential therapeutic targets
Therapeutic agent discovery eg. HTS, phage display, gene therapy development
Therapeutic agent development inc. preclinical testing
Translation to humans (eg. Phase I)
Translation to patients
(eg. Phase II,III)
Translation to practice
Translation to populations
Experiment

Strategic Plan

We have developed a Strategic Plan for the period 2019-2023 that outlines four strategic aims associated with support of a network of Australian translational research infrastructure.

Vision

For the Australian research community to have access to world class research infrastructure to enable efficient translation of therapeutics to improve human health.

Petri Dishes

Mission

TIA will enable and accelerate the translation of research discovery along the therapeutic development pipeline by investing in world class research infrastructure facilities so they are coordinated, comprehensive, accessible and responsive to the needs of the Australian translational research community.

TIA Board

TIA is a not-for-profit company limited by guarantee, and is governed by applicable legislation. TIA is overseen by an independent, skills-based Board that meets monthly, and a Governance, Audit and Risk Committee chaired by the Company Secretary that meets every 2 months. The Board members are knowledgable individuals with extensive experience in the public, private and not-for-profit sectors.

Chair

Terry Portrait.jpg

Mr Terry Slater AM
BSc, BEc, MPH, MAICD, FAIM

Rob Anderson.JPG.jpg

Mr Rob Anderson
FCA, FAICD

Company Secretary

Mr Anderson was the Managing Director of Orthogen Australia, which operated in the cell therapies sector. He is also principal of Anderson Business Consultants. Rob has significant experience consulting to government and industry. He has extensive commercial and financial experience in a diverse range of industries and business structures, including as Partner (Audit and Advisory) at Deloitte Touche Tohmatsu. 

Liz Furler1_0.jpg

Ms  Liz Furler
B.A (Social Work), Member of the 
Public Health Association of Australia

Ms Furler has extensive experience in the health and education sectors. Previous positions include Chief Executive Officer of Principals Australia, Executive Director with the Department of Education and Children’s Services in South Australia, Executive Director of the TRACsa, GM of ANTA (Melbourne) CEO of RACGP, First Assistant Secretary for the Commonwealth Health Services and Public Health Divisions and Principal Adviser to Commonwealth Department of Human Services and Health. Earlier positions included senior roles with the government health sectors of SA, Tasmania and the Commonwealth. 

Terry has held a number of Board positions apart from being Chair of TIA including as a Director and Company Secretary for DrinkWise Aus Ltd, Strategic Financial Advisor to the Board of Principals Aus and Chair of the National Food Authority Board. He led the work to establish National Statutory Schemes involving the Chairing of Inter-departmental Committees, and Commonwealth, State and Territory working parties and committees to create the ANZFA, ARPANSA, OGTR, the Treaty establishing the ANZFA and the Treaty establishing the future creation of the ANZ Therapeutic Products Agency. He was National Manager of the TGA and CEO of Australians Donate. He has played significant roles in Public Health policy and regulation.

Judith_Whitworth.jpg

Prof Judith Whitworth AM
MBBS, MD, PhD, DSc (Melb),HonDSc (Glasgow), FRACP, FAICD, FTSE, FAHMS (hon), MD (hon), Syd, MD (hon) UNSW,  D Lett (hon) CDU, LLD (hon) Melb

Prof Whitworth is an Emeritus Professor at ANU where she was previously Director of the John Curtin Schools of Medical Research. She is a Fellow of the Australian Academy of Technological Sciences and Engineering, the Royal Australasian College of Physicians, and the Australian Institute of Company Directors.

 

Professor Whitworth has chaired the Medical Research Committee of the NHMRC and is a Past-President of the Australian Society for Medical Research, and the High Blood Pressure Research Council of Australia as well as an Honorary Life Member of the ANZ Society of Nephrology.

Ross-McKinnon1-1024x1024.jpg

Prof Ross McKinnon
B Pharm (SAIT), B Sc (Hons) (Flinders), 
PhD (Flinders), MAICD

Prof McKinnon is an academic pharmacist with contributions spanning pharmaceutical research, policy and education. Attracting over $26 million, his research has produced more than 150 original papers, multiple patent families and spin-off companies.

Ross is the former Vice-President of the International Pharmaceutical Federation (FIP), which represents more than three million pharmacists and Pharmaceutical Scientists globally. He was elected to the position of Chair, FIP Board of Pharmaceutical Sciences in 2020.

TIA Management Team

TIA's management includes skilled and qualified individuals with a range of skills and experience.

The CEO is based in Brisbane at the Griffith Institute for Drug Discovery, co-located with Compounds Australia.

SN.jfif

Dr Stuart Newman 
GAICD

Chief Executive Officer

Located at GRIDD, Griffith University

Board_StellaClark.jpg

A/Prof Stella Clark AM
GAICD

Scientific Advisor

Located in Melbourne

MJ_Chua1d.jpg

Dr MJ Chua
 

John has over 20 years’ experience in human based healthcare R&D for pharmaceutical companies, biotech’s and world leading academic institutes. He is an experienced stakeholder manager and collaborator who has succeeded in early stage drug development and clinical trials management gaining a comprehensive understanding of the path to market for new drug entities.

 

Project management from high throughput drug discovery for multiple diseases encompassing cancer, tropical diseases and immunotherapeutic targets, through to clinical trials with a deep understanding of the pre-clinical to regulatory pathways to develop new therapies for approval by the TGA & FDA.

LB_edited.jpg

Lesley Bath
Dip Primary Teaching, Grad Dip Education

Office Manager

Located at TIA Melbourne Office

Lesley has been a consultant office manager for TIA Melbourne since late 2016 after a long career in Education with positions in teaching and administration and tertiary education roles at two Queensland universities. Lesley works part-time and is responsible for the Melbourne office in Collins Street, supporting the Board of Directors and the Governance & Risk committee. Lesley is also a Director of a not-for-profit company  dedicated to improving the health and education of orphaned children in Kenya.

Mr Ben Hughes
 

Ben Hughes.jpg

Director of Strategic Development,

National Biologics Facility

Located at AIBN,UQ

Ben brings over 20 years of experience in commercializing biologics with a proven track record of developing successful teams and implementing compliant systems for cGMP manufacturing in both Australia and the US.

 

Ben has extensive experience in facility design and start-up, and delivering for his customers in bringing a broad range of vaccines and biologics products through tech transfer from process development through to GMP manufacture and commercialization. 


Ben previously worked at Patheon by Thermo Fisher, The University of Queensland, Merck and Co, Inc., and CSL, and is a graduate of the University of New South Wales Bioprocess (Chemical) Engineering.

Heather completed her PhD in viral immunology at Imperial College before moving to Sydney for a post-doc at Westmead. Since then she has had a career spanning basic science, preclinical and clinical research in immunology and oncology.

Heather has a track record of enabling and developing research programs including proof of concept studies and commercially successful projects. Heather works with researchers to understand their unique circumstances. She has diverse project management expertise, from planning and executing preclinical studies to database migration.

Heather brings her diverse experience to TIA to enable researchers within the cell and gene space to access manufacturing facilities and enhance translation of novel therapies to the clinic.

John_Parisot 4_edited.jpg

Dr John Parisot
 

Business Development Manager, Small Molecules Capability

Located at MIPS, Monash Uni

           Part time: Mon,Tues and Thurs

John has over 20 years’ experience in human based healthcare R&D for pharmaceutical companies, biotech’s and world leading academic institutes. He is an experienced stakeholder manager and collaborator who has succeeded in early stage drug development and clinical trials management gaining a comprehensive understanding of the path to market for new drug entities. Project management from high throughput drug discovery for multiple diseases encompassing cancer, tropical diseases and immunotherapeutic targets, through to clinical trials with a deep understanding of the pre-clinical to regulatory pathways to develop new therapies for approval by the TGA & FDA.

Stella Clark joined TIA as Chair of the Australian Therapeutic Pipeline in 2016 and also serves as a Scientific adviser to the Board. She has unique expertise and genuine interest in facilitating scientific endeavours across organisations both public and private. Stella has worked at executive levels and is currently working with TIA to develop the Pipeline.

In 2019 Stella became a member of the Order of Australia for her significant service to medical research as an advocate for improved standards.

Program Manager

Located at GRIDD, Griffith University

MJ has diverse experience and background. After graduating with Bachelor of Science degree, she worked as an administration and marketing assistant in a start-up aquaculture company based in Kuala Lumpur, Malaysia. She then pursued a research-based Master's degree.

Subsequently, she worked as a research executive in a market research firm for healthcare and pharmaceutical sectors in the Asia Pacific, Middle East and Africa region. Prior to joining TIA, MJ worked as a Research Fellow at Griffith University.

Since completing a PhD in Antarctic Biology from the University of Tasmania, Stuart has built up considerable experience of science policy, pharmaceutical R&D, grant funding, IP management, business development and commercialisation in the university and not-for-profit sectors.

Stuart joined TIA as CEO in 2017. Under his leadership, TIA has focussed investment on the gap between research and development of high-value therapeutics, including pharmaceuticals, biologics, vaccines and cell & gene therapies. He also devised an innovative infrastructure access voucher scheme. He is a graduate of the Australian Institute of Company Directors

Scientific Engagement Manager, Cell and Gene Therapies Capability

Located at RPAH, NSW

Part time: Mon - Thurs

HD headshot.jpg

Dr Heather Donaghy


Heather completed her PhD in viral immunology at Imperial College before moving to Sydney for a post-doc at Westmead. Since then she has had a career spanning basic science, preclinical and clinical research in immunology and oncology.

Heather has a track record of enabling and developing research programs including proof of concept studies and commercially successful projects. Heather works with researchers to understand their unique circumstances. She has diverse project management expertise, from planning and executing preclinical studies to database migration.

Heather brings her diverse experience to TIA to enable researchers within the cell and gene space to access manufacturing facilities and enhance translation of novel therapies to the clinic

Facility Leadership

Kathy Andrews_5_edited.jpg

Prof Katherine Andrews

Director, GRIDD

Compounds Australia

Baell.jpg

Prof Jonathan Baell

Director

 Australian Translational Medicinal Chemistry Facility

Dr Benedict (Ben) Carnley.jpg

Dr Ben Carnley

Acting Director

 Cell and Tissue Therapies Western Australia

Susan-Charman.png

Prof Susan Charman

Director

Centre for Drug Candidate Optimisation

LHawkey PORTRAIT April 2020.jpg

Dr Leanne Hawkey

Facility Manager

 Australian Translational Medicinal Chemistry Facility

Darron Laing_Q-Gen.jpg

Darron Laing

Facility Manager

Q-Gen Cell Therapeutics

Susie-Nilsson.jpg

Prof Susie Nilsson 

Director

National Biologics Facility,

Vic Node

john+rasko_edited.jpg

Prof John Rasko AO

 

Director

Cell and Molecular Therapies

Leon Scott.JPG.jpg

Dr Leon Scott

General Manager

Q-Gen Cell Therapeutics

Trent Munro_b.jpeg

Prof Trent Munro

Director

National Biologics Facility,

Qld Node

Moana Simpson_2.jpg

Moana Simpson

Facility Manager​/ Acting Strategic Business Manager

Compounds Australia

Maree Smith2_edited.jpg

Em Prof Maree Smith AC

 

Director

Centre for Integrated Preclinical Drug Development

Melina%20Willson_edited.jpg

Dr Melina Wilsson

Facility Manager​

ANZCTR

Dominic-Wall-2-1.jpg

A/Prof Dominic Wall

CSO Cell Therapies Pty Ltd

 PeterMac Centre of Excellence in Cellular Immunotherapy